ICT-23

N/A

Report date: 2025/03/19 11:14:17

Base Information

Drug NameICT-23

Drug Alias NameICT-23

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionButyrophilin Subfamily 2 Member A3, Pseudogene inhibitorsButyrophilin subfamily 2 member A2 inhibitorsButyrophilin subfamily 2 member A1 inhibitors

TargetsButyrophilin Subfamily 2 Member A3, PseudogeneButyrophilin subfamily 2 member A2Butyrophilin subfamily 2 member A1

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImCheck Therapeutics SAS

China Registration ClassN/A

Develop Information

Active CompaniesImCheck Therapeutics SAS

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A